Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.48 |
| ▸ | REN | P00797 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318401 | 1.00 | CTSK (0.49) | CTSKMAPK1UTS2RRENBCHE | |
| SCHEMBL7400619 | 0.87 | UTS2R (0.62) | MAPK1UTS2RSCN9A | |
| SCHEMBL7415020 | 0.87 | UTS2R (0.62) | MAPK1UTS2RSCN9A | |
| SCHEMBL7402928 | 0.87 | UTS2R (0.62) | MAPK1UTS2RSCN9A | |
| SCHEMBL7403794 | 0.85 | UTS2R (0.55) | CTSKMAPK1UTS2RRENBCHE | |
| SCHEMBL7407107 | 0.82 | UTS2R (0.61) | MAPK1UTS2R | |
| SCHEMBL7408984 | 0.80 | UTS2R (0.65) | UTS2R | |
| SCHEMBL7409507 | 0.79 | HRH2 (0.55) | CTSKMAPK1UTS2RRENSCN9A | |
| SCHEMBL65855 | 0.78 | CACNA1B (0.60) | CTSKMAPK1REN | |
| SCHEMBL16497945 | 0.78 | CACNA1B (0.60) | CTSKMAPK1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | CTSK 1/4885MAPK1 2421/4885UTS2R 4088/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885MAPK1 2113/4885UTS2R 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.